Programmatic approach: An innovative model for drug development that delivers speed and flexibility from candidate to proof-of-concept
It is estimated that 70-80% of biotech firms still follow a study-by-study approach for their drug development program, often driven by investor requirements and cash flow limitations.
Finding commercial success by integrating development, regulatory and market access strategies from the get-go
When bringing a drug to market, there is a range of scientific, clinical, regulatory and market access challenges that pharmaceutical and biotechnology companies face.
Patients are using powerful drugs and medical devices, which are extremely efficient at enhancing and saving lives, but can come with complicated side effects.
Many people take for granted that the medication they have been prescribed by their physician will adequately treat or cure their ailment. Yet the reality is that a large number...
Functional Service Providers: A flexible trial staffing model that’s capable of taking on biomarker data management
As large pharma, biotech, and medical device organizations feel the economic pinch of escalating cost, stricter regulations, and fiercer competition, many seek new ways to cut the costs of development...